BridgeMD
Ampicillin and ceftriaxone for the treatment of Enterococcus faecalis infective endocarditis.
EU CTIS ID: 2024-511719-40-00
What this study is testing
To demonstrate that continuous infusion ampicillin-ceftriaxone administration is non-inferior in efficacy to standard treatment in patients with Enterococcus faecalis infective endocarditis defined as frequency of disease recurrence.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients (18 years of age or older)
- Possible or definitive diagnosis of infective endocarditis due to Enterococcus faecalis according to the Duke-ISCVID criteria
- Signed informed consent of patients
You likely can't join if
- Allergy to penicillins or cephalosporins
- Pregnancy and lactation
- Polymicrobial infection including microorganisms different to E. faecalis
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.